Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 4:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: AIDS Vaccines Clear all
Terminated Phase 1 Interventional

Safety, Reactogenicity and Immunogenicity of HB-502 and HB-501 Versus Placebo in People With HIV on Suppressive ART

NCT06430905
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
HB-502 and HB-501 alternating 2-vector therapy Dose Level 1, HB-502 and HB-501 alternating 2-vector therapy Dose Level 2, Placebo
Biological · Other
Lead sponsor
Hookipa Biotech GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Orlando, Florida • Decatur, Georgia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

NCT00001031
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 60 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 26, 2026, 4:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials

NCT03337906
View directory record Official record
Conditions
HIV Infections
Interventions
Observation
Other
Lead sponsor
HIV Vaccine Trials Network
Network
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
13
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2022 · Synced Jun 26, 2026, 4:01 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

HIV-1 Vaccine Test in Uninfected Adult Volunteers

NCT00045838
View directory record Official record
Conditions
Healthy
Interventions
VCR-HIVDNA006-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 1Phase 2 Interventional

Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection

NCT00125099
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
5
States / cities
San Diego, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study

NCT03560258
View directory record Official record
Conditions
HIV Infections
Interventions
p24CE1/2 pDNA vaccine, p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine, Full-length p55^gag pDNA vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventative Misconception Intervention

NCT01049139
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
1-sided messages, 2-sided messages
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 19 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
4
States / cities
San Francisco, California • New Orleans, Louisiana • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

NCT00459316
View directory record Official record
Conditions
HIV Infections, Meningitis
Interventions
Quadrivalent meningococcal conjugate vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
35
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 2 Interventional

Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

NCT00013663
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Jun 26, 2026, 4:01 PM EDT
Terminated Phase 1 Interventional Results available

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

NCT00798265
View directory record Official record
Conditions
Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
Interventions
Gardasil, Survey
Biological · Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 26 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus

NCT00000683
View directory record Official record
Conditions
HIV Infections
Interventions
HIVAC-1e, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1993
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jun 26, 2026, 4:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders

NCT05791851
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Vaccine Response Impaired
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 109 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Jun 26, 2026, 4:01 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

NCT00865566
View directory record Official record
Conditions
HIV Infections
Interventions
DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
2,504 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

NCT00000832
View directory record Official record
Conditions
HIV Infections
Interventions
MF59, rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1998
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths

NCT00107042
View directory record Official record
Conditions
Hepatitis B
Interventions
Recombivax, Twinrix
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 17 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers

NCT04725877
View directory record Official record
Conditions
HIV I Infection
Interventions
VIR-1111, Placebo
Biological · Drug
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Seattle, Washington • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 2 Interventional Results available

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

NCT00339040
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV), Placebo/QHPV
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 12 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
32
States / cities
Alhambra, California • Long Beach, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 1 Interventional

Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine

NCT01092611
View directory record Official record
Conditions
AIDS
Interventions
Blood collection, GSK HIV vaccine 732462
Procedure · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
11
States / cities
Bakersfield, California • Fort Lauderdale, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DCVax Plus Poly ICLC in Healthy Volunteers

NCT01127464
View directory record Official record
Conditions
HIV-1 Infection, HIV Infection, Healthy Volunteers
Interventions
DCVax-001, Poly-ICLC, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 1 Interventional

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)

NCT00000777
View directory record Official record
Conditions
HIV Infections, Pregnancy, HIV Seronegativity
Interventions
gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
2
States / cities
New Haven, Connecticut • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jun 26, 2026, 4:01 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Immunologic Memory (Supp. of ATN 024)

NCT00142753
View directory record Official record
Conditions
HIV Infections
Interventions
Engerix B, Twinrix for ATN 024, Recombivax, Twinrix for ATN 025
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 25 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
4
States / cities
Los Angeles, California • San Franciso, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Jun 26, 2026, 4:01 PM EDT
Not listed Not applicable Interventional

Pilot Study to Determine the Safety and Efficacy of Gardasil Against the Human Papilloma Virus (HPV) in HIV-infected Men

NCT00666107
View directory record Official record
Conditions
Anal Cancer, HIV Infections
Interventions
Gardasil
Biological
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Jun 26, 2026, 4:01 PM EDT